Bexitrol-F HFA 25/250 Inh Salmeterol 25 + Fluticasone 250 Mcg/Act 1’s
KSh 2,999.00
The Bexitrol-F HFA 25/250 Inhaler is a medication that combines Salmeterol, a long-acting beta-agonist (LABA), and Fluticasone, a corticosteroid. It is used for the management of asthma and chronic obstructive pulmonary disease (COPD). By relaxing the muscles in the airways and reducing inflammation, this dual-action inhaler helps to make breathing easier. Each actuation of the inhaler contains 25 mcg of Salmeterol Xinafoate and 250 mcg of Fluticasone Propionate.
Inhalers
Suggested Use
Bexitrol-F HFA is prescribed for the long-term management of asthma in individuals aged 12 years and above and the symptomatic relief of chronic obstructive pulmonary disease (COPD) in adults, including chronic bronchitis and emphysema.
- The recommended dosage for asthma is one inhalation in the morning and one in the evening, with the possibility of adjusting the dose according to the severity of the condition and the patient’s response.
- For COPD, one inhalation should be taken twice daily.
Warning
- Bexitrol-F HFA is not for immediate relief of acute bronchospasm or asthma attacks. Always carry a quick-acting inhaler for emergencies.
- It is contraindicated in patients with hypersensitivity to Salmeterol, Fluticasone, or any other component.
- Use caution in patients with cardiovascular conditions.
- Prolonged use of Fluticasone can result in adrenal suppression.
- Monitor for systemic corticosteroid effects. Fluticasone may mask or worsen infections in the mouth and respiratory tract.
- Rinse mouth after inhalation to lower the risk of oral thrush.
- Long-term use may decrease bone mineral density. Monitor patients at risk for osteoporosis. Monitor growth in pediatric patients.
- Extended use may increase the risk of glaucoma and cataracts.
- Store at room temperature, away from sunlight and heat. Keep out of reach of children. Do not puncture or burn the inhaler. Shake well before each use. Prime if new or unused for a week.